BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 18005118)

  • 1. Alopecia areata: topical immunotherapy treatment with diphencyprone.
    Avgerinou G; Gregoriou S; Rigopoulos D; Stratigos A; Kalogeromitros D; Katsambas A
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):320-3. PubMed ID: 18005118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year experience in the treatment of alopecia areata with DPC.
    El-Zawahry BM; Bassiouny DA; Khella A; Zaki NS
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):264-9. PubMed ID: 19744175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).
    Galadari I; Rubaie S; Alkaabi J; Galadari H
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):397-401. PubMed ID: 14768526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.
    Cotellessa C; Peris K; Caracciolo E; Mordenti C; Chimenti S
    J Am Acad Dermatol; 2001 Jan; 44(1):73-6. PubMed ID: 11148480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alopecia areata in children: treatment with diphencyprone.
    Schuttelaar ML; Hamstra JJ; Plinck EP; Peereboom-Wynia JD; Vuzevski VD; Mulder PG; Oranje AP
    Br J Dermatol; 1996 Oct; 135(4):581-5. PubMed ID: 8915150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
    Aghaei S
    BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
    Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F
    Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive model for immunotherapy of alopecia areata with diphencyprone.
    Wiseman MC; Shapiro J; MacDonald N; Lui H
    Arch Dermatol; 2001 Aug; 137(8):1063-8. PubMed ID: 11493099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical immunomodulation with diphenylcyclopropenone for alopecia areata: the Lebanese experience.
    El Khoury J; Abd-el-Baki J; Succariah F; Abbas O; Kibbi AG; Kurban M
    Int J Dermatol; 2013 Dec; 52(12):1551-6. PubMed ID: 24134785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPCP for the treatment of alopecia areata.
    Bolduc C; Shapiro J
    Skin Therapy Lett; 2000; 5(5):3-4. PubMed ID: 10854342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of alopecia areata with diphencyprone].
    Suditu G; Toma A; Voiculescu M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):760-2. PubMed ID: 12092234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
    Durdu M; Özcan D; Baba M; Seçkin D
    J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata.
    Tobin DJ; Gardner SH; Lindsey NJ; Hoffmann R; Happle R; Freyschmidt-Paul P
    Eur J Dermatol; 2002; 12(4):327-34. PubMed ID: 12095876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
    Simonetti O; Lucarini G; Bernardini ML; Simoncini C; Biagini G; Offidani A
    Br J Dermatol; 2004 May; 150(5):940-8. PubMed ID: 15149507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphencyprone in the treatment of alopecia areata.
    Happle R; Hausen BM; Wiesner-Menzel L
    Acta Derm Venereol; 1983; 63(1):49-52. PubMed ID: 6191489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up.
    Gordon PM; Aldrige RD; McVittie E; Hunter JA
    Br J Dermatol; 1996 May; 134(5):869-71. PubMed ID: 8736327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pronounced perifollicular lymphocytic infiltrates in alopecia areata are associated with poor treatment response to diphencyprone.
    Freyschmidt-Paul P; Hamm H; Happle R; Hoffmann R
    Eur J Dermatol; 1999 Mar; 9(2):111-4. PubMed ID: 10066958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C; Gupta S; Kanwar AJ
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alopecia areata: a long term follow-up study of 191 patients.
    Tosti A; Bellavista S; Iorizzo M
    J Am Acad Dermatol; 2006 Sep; 55(3):438-41. PubMed ID: 16908349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse corticosteroid therapy for alopecia areata: study of 139 patients.
    Nakajima T; Inui S; Itami S
    Dermatology; 2007; 215(4):320-4. PubMed ID: 17911990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.